News Research Clinical Trials

Neurosymbolic, Multiagent AI Speeds Oncology Clinical Trial Matching by Fourfold

A prospective study presents a multi-agent clinical trial matching architecture that outperforms standalone large language models and reduces screening time compared with manual review.

April 14, 2026 By Julia Cipriano, MS, CMPP 5 min read
Share
-0:00/0:00

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content